Inhibition of salivary glands to reduce uptake of radioactive Iodine

Phase 2

• Conditions: Iodine accumulation in salivary glands.; Iodine biodistribution; 10043739; 10039404

• Registration Number: NL-OMON46303
• Lead Sponsor: Antoni van Leeuwenhoek Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

- In follow-up after treatment for thyroid carcinoma
- Received only one treatment with Iodine-131
- Currently no signs of recurrence

Exclusion Criteria

- Age < 18y
- Inability to provide informed consent
- Planned changes in treatment/medication between the baseline scan and intervention scan
- History of disease or treatment involving the salivary glands (Malignant or benign tumour, sialoadenitis, stone, surgery, SLE, RT to head-neck, etc)
- Currently on anticholinergic medication
- Contra-indications for anticholinergic medication (Glaucoma, obstructed digestive/urological tract, megacolon, ileus, tardive dyskinesia)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary parameter is the total quantified uptake of Iodine-123 on planar<br /><br>scintigraphy in all macroscopic salivary glands together (with and without GPB)<br /><br>measured at 4h after administration. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary parameters are the uptake in salivary glands at 24h, uptake in<br /><br>stomach and bowels, and uptake in other normal tissues throughout the body.</p><br>